Is cervical carcinoma in situ cancer?

Cervical carcinoma in situ is a precancerous lesion that has not yet broken through the basement membrane to form invasive cancer. The pathological characteristics of cervical carcinoma in situ are abnormal proliferation of epithelial cells but no stromal infiltration, so it is not cancer in the strict sense.

Cervical carcinoma in situ refers to cervical intraepithelial neoplasia reaching a high-grade stage, with significant cellular atypia but limited to the epithelial layer. The International Federation of Gynecology and Obstetrics classifies it as cervical intraepithelial neoplasia grade III, which is a curable precancerous stage. The lesions can be completely removed through local treatment such as cervical conization, and the five-year survival rate is close to 100%. At this stage, cancer cells have not acquired the ability to invade and metastasize, and they will not exhibit the typical lymphovascular infiltration characteristics of cancer.

Without timely intervention, approximately 30% of cervical carcinoma in situ may progress to invasive cervical cancer. When abnormal cells break through the basement membrane and grow into deeper tissues, it is defined as a true malignant tumor. At this time, cancer cells can metastasize through the lymphatic system, and comprehensive treatments such as extensive hysterectomy combined with radiotherapy and chemotherapy are required. Pathological diagnosis requires the observation of stromal infiltration and vascular tumor thrombus to confirm the diagnosis of cervical cancer.

Regular cervical cancer screening can effectively detect stage lesions of carcinoma in situ. It is recommended that sexually active women undergo cervical cytology examination every three years, and high-risk groups can be combined with HPV testing. Measures such as maintaining a single sexual partner, getting the HPV vaccine, and avoiding smoking can help prevent disease progression. After diagnosis, standardized treatment should be completed as directed by the doctor, and signs of recurrence should be monitored for long-term follow-up.